What you need to know on donanemab
On May 3, American drug company Eli Lilly and Company released some results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease.

On May 3, American drug company Eli Lilly and Company released some results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease.